Categories
Organisations we regulate
You can find more guidance and information about cannabis-based medicinal products in the links provided on this page.
National Institute for Health and Care Excellence (NICE):
- Cannabis-based medicinal products
- NICE guideline NG144 (November 2019): prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
- Technology appraisal guidance on cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
NHS England:
Royal College of Physicians:
General Medical Council:
- Information for doctors on cannabis-based products for medicinal use and
- Prescribing unlicensed medicines.
Medicines and Healthcare products Regulatory Agency:
- The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in humans ‘specials’
- A guide to what is a medicinal product - MHRA Guidance Note 8.
Care Quality Commission:
Legislation:
- The Misuse of Drugs Regulations 2001
- Regulation 16A of the Misuse of Drugs Regulations 2001: further information on ordering, supply and use of cannabis-based medicinal products.
- The Misuse of Drugs (amendments) (cannabis and licence fees) (England, Wales and Scotland) Regulations 2018
- Health and Social Care Act 2008
- Care Quality Commission (Registration) Regulations 2009
- research evidence and guidance from international bodies (such as the European Medicines Agency)
- Interim guidance from professional organisations (such as the Royal College of Physicians, the British Paediatric Neurology Association and the Association of British Neurologists).